Abstract. Tetrahydrobiopterin (BH4) deficiency has been suggested to be an important factor in vascular endothelial dysfunction. In this study, we investigated the influence of decreased BH4 level produced by administration of 2,4-diamino-6-hydroxypyrimidine (DAHP), a specific inhibitor of the rate-limiting enzyme of BH4 synthesis, on vascular endothelial function in anesthetized rats. Wistar rats were given DAHP (0.1 -1.0 g / kg, i.p.) or the vehicle 5 h before the experiment. Depressor responses to the endothelium-dependent vasodilator acetylcholine and the endothelium-independent vasodilator sodium nitroprusside were tested. After the experiment, blood and thoracic aorta were taken for estimating their BH4 levels and plasma concentrations of nitrite plus nitrate. DAHP produced marked decreases in BH4 levels in plasma and aorta in a doserelated manner. Baseline values for hemodynamics were not affected by DAHP. Depressor responses to acetylcholine were attenuated with the highest dose of DAHP (1.0 g / kg) but not with DAHP (0.3 g /kg), although similar decreases in BH4 levels were seen with these two doses of DAHP. Treatment with DAHP at each dose did not decrease plasma concentrations of nitrite plus nitrate. These findings suggest that a decrease in BH4 levels by acute inhibition of de novo BH4 synthesis does not necessarily cause endothelial dysfunction.
Introduction
Nitric oxide (NO) plays a key role in the regulation of vascular tone and blood pressure as a primary mediator of endothelium-dependent vasodilatation. Impairment of normal NO production by endothelial NO synthase (eNOS) is an important factor of endothelial dysfunction in vascular disease states including diabetes, hypertension, and hypercholesterolemia (1) . A critical aspect of NOS function is the requirement for the cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4), and limited availability of BH4 causes fundamental alterations of NOS, resulting in not only diminished NO production but also superoxide production through uncoupled NOS (2) .
Previous experimental studies with streptozotocininduced diabetes mice (3), genetically non-obese type II diabetes rats (4), deoxycorticosterone acetate (DOCA)-salt hypertensive mice (5, 6) , and hyperlipidemic rabbits (7) have demonstrated that vasorelaxations with the endothelium-dependent agonist acetylcholine (ACh) in these vascular pathophysiological models are attenuated and vascular levels of BH4 are markedly diminished. In addition, supplementation with BH4 has been shown to improve eNOS dysfunction in various animal models of cardiovascular diseases, as well as in patients with hypercholesterolemia, diabetes mellitus, and essential hypertension and in chronic smokers (8) . These findings suggest that decreased levels of BH4 may lead to endothelial dysfunction. However, it is still unclear whether acute reduction in BH4 levels causes in vivo endothelial dysfunction, and it remains to be determined whether there is a close relationship between BH4 levels and endothelial function. BH4 is formed by sequential three steps catalyzed by GTP cyclohydrolase I (GTPCH), 6-pyruvoyltetrahydroprerin synthase, and sepiapterin reductase in a de novo biosynthetic pathway, and intracellular BH4 levels are usually regulated by the activity of GTPCH that is the rate-limiting enzyme (9, 10) . The present study was thus conducted to examine the effect of decreased BH4 level produced by administration of 2,4-diamino-6-hydroxypyrimidine (DAHP), a selective inhibitor of GTPCH (11, 12) , on endothelial function assessed by testing depressor responses to the endothelium-dependent vasodilator ACh and the endothelium-independent vasodilator sodium nitroprusside (SNP) and by estimating plasma concentrations of NO metabolites, which would reflect a tonic production by eNOS, in anesthetized rats.
Materials and Methods

Animals
The animals used in the study were handled in accordance with Guidelines for the Animal Experimentation of the University of the Ryukyus and the experimental protocol was approved by the Animal Care and Use Committee of the institution.
Male Wistar rats weighing 280 -560 g supplied by Kyudo (Kumamoto) were used at 10 -18 weeks of age.
Surgical preparation of rats
Rats were anesthetized with sodium pentobarbital at 60 mg / kg, i.p. and placed on a heating plate to maintain the body temperature. Additionally, sodium pentobarbital at 40 mg / kg was subcutaneously injected to maintain a constant level of anesthesia throughout the experimental period. The trachea was cannulated to ensure patency of the airway. A heparinized catheter was inserted into the left femoral vein for intravenous administration of drugs. Aortic pressure (AoP) was measured through a catheter that was inserted into the aorta via the right carotid artery. The catheter was connected to a pressure transducer (TP-400T; Nihon Kohden, Tokyo). Heart rate was continuously monitored with a cardiotachometer (AT-601G, Nihon Kohden) triggered by the electrocardiogram. A flow probe (1R2820; Transonic Systems, Ithaca, NY, USA), connected to an ultrasonic flowmeter (T106, Transonic Systems), was positioned around the root of the right femoral artery for the measurement of femoral arterial blood flow (FBF). Femoral vascular resistance (FVR) was calculated from the following equation: FVR (mmHg ⋅ min /mL) = mean AoP/FBF. Data were continuously recorded on a pen recorder (8K-23; NEC San-ei Instrument, Tokyo).
Experimental protocol
DAHP (0.1, 0.3, or 1.0 g / kg, i.p.) or the vehicle was given 5 h before the beginning of the experiments. The rats were allowed to stabilize for at least 30 min after completion of the operation. Before drug challenges, baseline values of cardiovascular parameters were measured. Each drug was injected into the left femoral vein in a bolus of 0.5 mL / kg.
Depressor responses, estimated by the peak reduction in diastolic AoP (dAoP), to intravenous (i.v.) bolus injections of acetylcholine (ACh; 0.05, 0.1, 0.2, and 0.5 μg / kg) and sodium nitroprusside (SNP; 1, 2, 5, and 10 μg /kg) were tested. The results were compared between treatment with DAHP at each dose and treatment with the vehicle alone. Additionally, depressor and pressor responses to L-isoproterenol (Iso, 0.1 μg/kg), a non NO-dependent vasodilator, and norepinephrine (NE, 1.0 μg/ kg) were tested.
Measurement of biopterins
Blood sample of 2 mL was taken with a syringe containing 2 μmol of 1,4-dithiothreitol (DTT) through the catheter inserted into the aorta via the right carotid artery just after completion of the experiment and collected in an EDTA-containing tube. Plasma was obtained by centrifugation at 3,000 rpm for 10 min. A 1-mL aliquot of plasma was deproteinized with 200 μL of 10% perchloric acid and then centrifuged at 4°C and 15,000 rpm for 10 min. The supernatant was stored at −30°C.
Fresh thoracic aorta was excised after bleeding, and homogenized in 10% (wt / vol) of extraction buffer [50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM DTT] using a glass mortar and pestle. The homogenate was centrifuged at 4°C and 15,000 rpm for 10 min. The supernatant was stored at −30°C.
Biopterin contents in plasma and aorta were determined by a high performance liquid chromatography system (LV-10AD; Shimadzu, Kyoto) according to the method of Fukushima and Nixon (13) with some modifications. The amount of BH4 was estimated from the difference between the total biopterin (acid oxidized biopterin level = BH4 + BH2 + biopterin) and alkalinestable biopterin (alkaline oxidized biopterin level = BH2 + biopterin).
Measurement of nitric oxide metabolites
A blood sample obtained in the same way as for BH4 analysis was deproteinized by addition of an equal volume of methanol. Plasma levels of nitrite and nitrate, NO metabolites, were measured by using the Griess method with an automated NO detector high-performance liquid chromatography system (ENO-20; Eicom, Kyoto), as described previously (14) .
Drugs
The drugs employed in this study were DAHP and SNP (Sigma, St. Louis, MO, USA), BH4 (Wako, Osaka), ACh (Dai-ichi, Tokyo), Iso (Nikken Kagaku, Tokyo), and NE (Sankyo, Tokyo). DAHP was dissolved in 10 mM phosphate-buffered saline (pH 6.5). The other drugs were dissolved in or diluted with saline.
Data analyses
The dose-response data were analyzed by analysis of covariance. For multiple comparisons between groups, one-way analysis of variance was used with the Dunnett post hoc test. The level for statistical significance was P < 0.05. All results are expressed as means ± S.E.M.
Results
Total biopterin and BH4 levels in plasma and aorta
As shown in Fig. 1 , plasma concentrations of total biopterin, which includes oxidized forms of BH4 such as dihydrobiopterin and biopterin, and BH4 in rats received three graded doses (0.1, 0.3, and 1.0 g / kg) of DAHP markedly decreased in a dose-related manner to 68%, 28%, and 32% and to 68%, 29%, and 21% of the corresponding control (118.2 ± 5.4 nM for total biopterin and 93.6 ± 4.2 nM for BH4), respectively. Total biopterin and BH4 contents in aorta of DAHP-treated rats also significantly diminished to 74%, 53%, and 72% and to 65%, 45%, and 46% of the control (108.1 ± 6.7 pmol / g wet weight for total biopterin and 84.3 ± 6.2 pmol / g wet weight for BH4), respectively Each reported data value is a mean ± S.E.M. Number in parenthesis shows number of animals in each group. **P<0.01 vs control. Fig. 2 . Effect of 2,4-diamino-6-hydroxypyrimidine (DAHP) on levels of total biopterin and tetrahydrobiopterin (BH4) in aorta. Each reported data value is a mean ± S.E.M. Number in parenthesis shows number of animals in each group. *P<0.05, **P<0.01 vs control. (Fig. 2) . These results indicate that 0.3 g /kg of DAHP may be a dose that causes nearly maximal decreases in BH4 levels in both plasma and aorta. Administration of 0.1 and 0.3 g /kg DAHP did not affect BH4 / total biopterin ratios in plasma and aorta as compared to those in control rats (Fig. 3) , whereas the ratios in 1.0 g/kg-DAHP group significantly decreased, indicating that oxidized forms of BH4 such as dihydrobiopterin increased.
Depressor responses to ACh and SNP
Baseline values of hemodynamic variables such as systolic and diastolic aortic pressure, femoral blood flow, heart rate, and femoral vascular resistance obtained just before the beginning of experiment were not significantly different between the control group and DAHP-treated groups ( Table 1) .
As shown in Fig. 4 , depressor responses (−7.8 ± 0.8, −14.4 ± 1.4, −22.6 ± 1.5, and −31.3 ± 2.0 mmHg from the baseline of 85.9 ± 5.1 mmHg) to graded doses (0.05, 0.1, 0.2, and 0.5 μg/ kg) of ACh, an endotheliumdependent NO-mediated vasodilator, were significantly attenuated (P<0.01) with the highest dose of DAHP (1.0 g /kg) as compared to those (−11.6 ± 1.1, −18.1 ± 1.3, −26.4 ± 1.5, and −34.9 ± 1.8 mmHg from the baseline of 87.7 ± 3.1 mmHg) seen in the control group, which were associated with insignificant changes in both heart rate (P = 0.34) and systolic aortic pressure (P = 0.07), indicating that the difference in depressor responses can be attributable mainly to different responsiveness of peripheral vascular resistance to ACh. However, 0.3 g / kg DAHP did not affect ACh-induced depressor responses despite comparable decreases in plasma and aorta BH4 levels with these two doses of DAHP ( Figs. 1 and 2) . In contrast, depressor responses to SNP (Fig. 4) , an endothelium-independent NO donor, and Iso (Fig. 5) , a non NO-mediated vasodilator, were not attenuated with any dose of DAHP. Significantly decreased NE pressor response was seen with 1.0 g / kg DAHP (P<0.05) but not with the lower doses of DAHP (Fig. 5) . 
Nitrite plus nitrate levels in plasma
Treatment with DAHP at each dose did not significantly affect plasma concentrations of nitrite plus nitrate, stable metabolites of NO, when compared with those in the vehicle-received control group (Fig. 6) . Neither the plasma nitrite nor the nitrate concentration in any DAHP group was significantly different from the respective value in the control group.
Discussion
The acute effect of decreased BH4 levels on endothelial function remains obscure, although previous studies with various animal models of diabetes, hypertension, and hyperlipidemia have demonstrated that endothelial dysfunction in these vascular pathophysiological conditions are associated with markedly diminished levels of BH4. This study thus addressed whether there is a simple relationship between BH4 levels and eNOS function even shortly after inhibition of BH4 synthesis as seen in the above pathophysiological status.
The present study demonstrates that single administration of DAHP produced marked and dose-related reductions in levels of BH4 as well as total biopterin in both plasma and aorta after a relatively short period. The extent to which DAHP treatment lessened plasma BH4 concentrations in rats is quite consistent with that after the same dosage of DAHP described in an early report (15) . The present data that BH4 levels in aortic tissue from DAHP (0.3 or 1.0 g / kg)-treated rats were below a half of those from control rats also seem compatible with previous findings obtained with the hyperphenylalaninemic mouse mutant (hph-1) displaying 90% deficiency in GTPCH activity in that the intracellular levels of BH4 in the aorta decreased to 50% of those in wild-type mice (16) . This perhaps implies that treatment with DAHP of 0.3 g /kg as well as 1.0 g /kg might be sufficient to cause approximately 90% inhibition of GTPCH activity, although it should be noted that there are distinct differences in experimental conditions, and further experiments such as measurement of GTPCH activity must be needed to confirm this speculation.
As expected from the fact that BH4 is an essential cofactor for eNOS that generates the potent endogenous vasodilator NO, treatment with the highest dose of DAHP significantly, but slightly, attenuated endothelium-dependent vasodilatation by ACh without affecting endothelium-independent vasodilatation by SNP or L-isoproterenol. These results are compatible with previous studies using isolated vessels treated with DAHP (17, 18) . We observed in a pilot study where DAHP (1.0 g / kg) repeatedly was given 18 and 5 h before the experiment that attenuation of ACh-induced depressor responses was also similar to that seen with the single dose. However, the difference in ACh-induced depressor responses between the 1.0 g / kg-DAHP group and the control group seems so small, whereas the former BH4 levels in plasma and aorta decreased to almost the minimum of 21% and 46% of the control, respectively. Furthermore, even treatment with DAHP at 0.3 g / kg failed to cause endothelial dysfunction as estimated by the endothelium-dependent depressor response and plasma nitrite plus nitrate levels, even though 0.3 g / kg of DAHP is considered to be nearly the maximum dose in decreasing endogenous BH4 content. In addition, no rise in baseline blood pressure was observed in DAHP-treated rats as shown in a recent report (19) . These results indicate that the effect of acute reduction in BH4 levels on in vivo endothelial function, especially for the regulation of resting blood pressure, may be, if any, apparently trivial. In line with the present findings, several in vitro studies have shown no difference in endothelium-dependent vasorelaxation after DAHP incubation (20) or in the hph-1 mouse mutant (16) . Our data thus suggest that the intracellular BH4 for maintaining the normal eNOS function is relatively small and insensitive to acute inhibition of de novo BH4 synthesis. BH4 synthesis occurs via two distinct pathways: a de novo synthetic pathway using GTP as a precursor and a salvage (recycling) pathway for preexisting dihydropterins such as dihydrobioptrin (9) . As indicated by Gross and Levi (21) , BH4 is synthesized in rat aorta predominantly from GTP, but a lesser amount derives from the pterin salvage pathway and may contribute to preserve eNOS activity. Therefore, it is suggested that acute administration of DAHP may reduce de novo synthesis of vascular BH4, but not constitutive concentrations of BH4, since the recycling pathway is intact. As an additional mechanism, Cosentino et al. (16) proposed that under conditions of BH4 deficiency, endothelium-dependent relaxations are in part mediated by eNOS-catalyzed production of oxygenderived free radicals such as hydrogen peroxide, a potent vasodilator (22) .
A significant decrease in BH4 /total biopterin ratio by treatment with 1.0 g /kg DAHP was observed, which was associated with reduced responses to ACh. These results indicate the possibility that the endothelial dysfunction might attribute to a decrease in this ratio, resulting from an increase in oxidized forms of BH4 such as dihydrobiopterin, rather than a decrease in the absolute amount of BH4. This view is supported by several lines of evidence provided by various investigations with insulin-resistant rats (23, 24) , inborn diabetic mice (25) , and DOCA-salt hypertensive rats (5) .
Conflicting with the present findings, in animal models of vascular disease including diabetes (3, 4, 26) , hypertension (5, 6) , and hyperlipidemia (7), endothelial dysfunction is shown to be associated with profoundly decreased BH4 levels to 4% -45% of the respective control. The reason why this discrepancy occurs is unknown at present, but this may be explained mainly by the differences in duration of drug-treatment or pathological states. It is obvious that further experiments will be needed to elucidate the potential roles of reactive oxygen species, the salvage pathway, and oxidized forms of BH4 in endothelial function in face of in vivo BH4 deficiency. For example, if DAHP is given in combination with an inhibitor of the salvage pathway such as methotrexate in order to produce exhaustive reductions in BH4 levels, further information might be obtained.
Interestingly, single treatment with DAHP (0.5 or 0.18 g/kg, i.p.) in rats has been shown to attenuate cerebral infarction in ischemic stroke (19) and to relieve neuropathic and inflammatory pain in the spared nerve injury model (27) . These findings may provide a new strategy, which could reduce selectively de novo BH4 synthesis, aimed at preventing neuronal injury after cerebral ischemic reperfusion and the establishment or maintenance of chronic pain. Since it is desirable for the therapeutic use of DAHP that inhibition of BH4 synthesis does not result in impairment of normal endothelial function by leaving the constitutive NOS function intact, the present findings, demonstrating that a significant decrease in BH4 levels produced by DAHP does not necessarily cause endothelial dysfunction, may support the idea that the inhibitor, if an appropriate dose less than the dose corresponding to 1.0 g/ kg, i.p. can be selected, may have potential as a remedy for these pathological states.
In conclusion, the present data show that a decrease in BH4 levels by acute inhibition of de novo BH4 biosynthesis with DAHP does not necessarily cause endothelial dysfunction and suggest that the normal eNOS function may be dependent not simply on the intracellular BH4 that can be affected by DAHP.
